Abstract：
To assess the efficacy and safety of urea in patients with hyponatremia and heart failure (HF).
This is a retrospective observational analytical study of patients with HF and hyponatremia (Na+ <135mmol/L). Forty-nine patients treated with urea and 47 patients who did not receive urea, all under standard treatment (according to usual clinical practice) for HF, were included and followed up at Álvaro Cunqueiro Hospital in Vigo (Spain) between January 2013 and May 2022. The study evaluated the normalization of sodium levels (Na >135mmol/L). The initial natremia at the start of oral urea treatment was 127±5.22 mmol/L, at 24h the sodium level was 128±2.47 (P<.009), and the mean on the day of normalization was 135.19±4.23mmol/L (P<.005). The average number of days to achieve sodium normalization was 5.03±2.37 days. The initial uremia at the start of urea treatment was 73±46.93mg/dL, and the mean on the day of Na+ normalization was 116.05±63.64mg/dL (P<.002). The average oral urea dose was 22.5g/day. No relevant adverse effects were observed, nor were there significant changes in creatinine levels.
Oral urea treatment, when added to standard treatment for short periods of time, is safe and effective in correcting natremia in patients with hypervolemic HF with hyponatremia.
This is a retrospective observational analytical study of patients with HF and hyponatremia (Na+ <135mmol/L). Forty-nine patients treated with urea and 47 patients who did not receive urea, all under standard treatment (according to usual clinical practice) for HF, were included and followed up at Álvaro Cunqueiro Hospital in Vigo (Spain) between January 2013 and May 2022. The study evaluated the normalization of sodium levels (Na >135mmol/L). The initial natremia at the start of oral urea treatment was 127±5.22 mmol/L, at 24h the sodium level was 128±2.47 (P<.009), and the mean on the day of normalization was 135.19±4.23mmol/L (P<.005). The average number of days to achieve sodium normalization was 5.03±2.37 days. The initial uremia at the start of urea treatment was 73±46.93mg/dL, and the mean on the day of Na+ normalization was 116.05±63.64mg/dL (P<.002). The average oral urea dose was 22.5g/day. No relevant adverse effects were observed, nor were there significant changes in creatinine levels.
Oral urea treatment, when added to standard treatment for short periods of time, is safe and effective in correcting natremia in patients with hypervolemic HF with hyponatremia.
摘要：
目的：评估尿素对低钠血症和心力衰竭（HF）患者的疗效和安全性。
结果：这是一项针对HF和低钠血症（Na+<135mmol/L）患者的回顾性观察性分析研究。49例接受尿素治疗的患者和47例未接受尿素治疗的患者，均在HF的标准治疗（根据通常的临床实践）下，在2013年1月至2022年5月期间，在Vigo（西班牙）的AlvaroCunqueiro医院进行了随访。该研究评估了钠水平的正常化(Na>135mmol/L)。口服尿素治疗开始时的初始血钠为127±5.22mmol/L，24h时钠水平为128±2.47（P<.009），正常当天的平均值为135.19±4.23mmol/L（P<.005）。实现钠正常化的平均天数为5.03±2.37天。尿素治疗开始时的初始尿毒症为73±46.93mg/dL，Na+正常化当天的平均值为116.05±63.64mg/dL(P<.002)。平均口服尿素剂量为22.5g/天。未观察到相关不良反应，肌酐水平也没有显著变化.
结论：口服尿素治疗，当短时间内加入标准治疗时，纠正高血容量HF伴低钠血症患者的低钠血症是安全有效的。
结果：这是一项针对HF和低钠血症（Na+<135mmol/L）患者的回顾性观察性分析研究。49例接受尿素治疗的患者和47例未接受尿素治疗的患者，均在HF的标准治疗（根据通常的临床实践）下，在2013年1月至2022年5月期间，在Vigo（西班牙）的AlvaroCunqueiro医院进行了随访。该研究评估了钠水平的正常化(Na>135mmol/L)。口服尿素治疗开始时的初始血钠为127±5.22mmol/L，24h时钠水平为128±2.47（P<.009），正常当天的平均值为135.19±4.23mmol/L（P<.005）。实现钠正常化的平均天数为5.03±2.37天。尿素治疗开始时的初始尿毒症为73±46.93mg/dL，Na+正常化当天的平均值为116.05±63.64mg/dL(P<.002)。平均口服尿素剂量为22.5g/天。未观察到相关不良反应，肌酐水平也没有显著变化.
结论：口服尿素治疗，当短时间内加入标准治疗时，纠正高血容量HF伴低钠血症患者的低钠血症是安全有效的。
